QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$11.47
$2.66
$32.75
$48.64M2.5795,409 shs43,300 shs
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.18
-2.5%
$0.20
$0.09
$3.59
$9.87M2.172.43 million shs582,115 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$6.97
+4.7%
$6.60
$3.04
$8.69
$89.70M0.7834,623 shs69,921 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00%0.00%0.00%0.00%+200.25%
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-6.25%+16.18%-22.98%+6.29%-93.21%
LifeVantage Co. stock logo
LFVN
LifeVantage
+0.91%+9.54%-4.17%+12.88%+94.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
2.9998 of 5 stars
0.05.01.72.73.31.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
2.50
Moderate Buy$17.50∞ Upside
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
1.75
ReduceN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$2.33M0.00N/AN/A($60.61) per share0.00
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$213.40M0.42$0.55 per share12.73$2.71 per share2.57

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/A
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$1.41N/AN/AN/AN/A-137.47%5/9/2024 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2330.30N/A1.40%19.96%9.48%5/2/2024 (Confirmed)

Latest CHMA, GRTX, BFRA, LFVN, and AGLE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/AN/AN/A  
1/30/2024Q2 2024
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A$0.10+$0.10$0.25N/A$51.62 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/A
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.142.01%N/A60.87%1 Years

Latest CHMA, GRTX, BFRA, LFVN, and AGLE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.03502.64%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
4.59
4.59
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
4.36
4.36
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%

Insider Ownership

CompanyInsider Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
6.60%
Biofrontera AG stock logo
BFRA
Biofrontera
N/A
Chiasma, Inc. stock logo
CHMA
Chiasma
8.30%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
6.90%
LifeVantage Co. stock logo
LFVN
LifeVantage
6.76%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
694.05 million3.78 millionOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3154.39 million50.64 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.87 million12.00 millionOptionable

CHMA, GRTX, BFRA, LFVN, and AGLE Headlines

SourceHeadline
LifeVantage to Announce Third Quarter Fiscal Year 2024 Results on May 2, 2024LifeVantage to Announce Third Quarter Fiscal Year 2024 Results on May 2, 2024
globenewswire.com - April 18 at 4:05 PM
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 21.7% in MarchLifeVantage Co. (NASDAQ:LFVN) Short Interest Down 21.7% in March
marketbeat.com - April 13 at 11:40 AM
Investing in LifeVantage (NASDAQ:LFVN) a year ago would have delivered you a 98% gainInvesting in LifeVantage (NASDAQ:LFVN) a year ago would have delivered you a 98% gain
finance.yahoo.com - April 5 at 9:56 AM
LifeVantage Co. (NASDAQ:LFVN) Short Interest UpdateLifeVantage Co. (NASDAQ:LFVN) Short Interest Update
marketbeat.com - March 30 at 9:21 AM
Lifevantage director Darwin Lewis buys shares worth $3,142Lifevantage director Darwin Lewis buys shares worth $3,142
investing.com - March 20 at 8:57 AM
LifeVantage Wraps Up Momentum Academy 2024 with a Focus on Entrepreneurship and GrowthLifeVantage Wraps Up Momentum Academy 2024 with a Focus on Entrepreneurship and Growth
globenewswire.com - March 18 at 8:00 AM
Is Now The Time To Look At Buying LifeVantage Corporation (NASDAQ:LFVN)?Is Now The Time To Look At Buying LifeVantage Corporation (NASDAQ:LFVN)?
finance.yahoo.com - March 15 at 7:59 PM
LFVN Jun 2024 10.000 callLFVN Jun 2024 10.000 call
finance.yahoo.com - March 9 at 3:50 PM
LifeVantage Transforms the Future of Skin Health and Radiance: Introducing the TrueScience® Activated Skin Care CollectionLifeVantage Transforms the Future of Skin Health and Radiance: Introducing the TrueScience® Activated Skin Care Collection
globenewswire.com - March 4 at 8:00 AM
Interested In LifeVantages (NASDAQ:LFVN) Upcoming US$0.035 Dividend? You Have Four Days LeftInterested In LifeVantage's (NASDAQ:LFVN) Upcoming US$0.035 Dividend? You Have Four Days Left
finance.yahoo.com - February 24 at 10:12 AM
Lifevantage Corp.Lifevantage Corp.
wsj.com - February 22 at 9:23 PM
TCTM, LFVN, THS among consumer staples moversTCTM, LFVN, THS among consumer staples movers
msn.com - February 16 at 1:40 PM
LifeVantage to Participate in the Winter Wrap Up MicroCap Rodeo ConferenceLifeVantage to Participate in the Winter Wrap Up MicroCap Rodeo Conference
finance.yahoo.com - February 16 at 8:39 AM
LifeVantage to Participate in the Winter Wrap Up MicroCap Rodeo ConferenceLifeVantage to Participate in the Winter Wrap Up MicroCap Rodeo Conference
globenewswire.com - February 16 at 8:00 AM
LifeVantage Appoints Dayton Judd to the Board of DirectorsLifeVantage Appoints Dayton Judd to the Board of Directors
finance.yahoo.com - February 15 at 4:15 PM
LifeVantage Appoints Dayton Judd to the Board of DirectorsLifeVantage Appoints Dayton Judd to the Board of Directors
globenewswire.com - February 15 at 4:05 PM
LifeVantage Announces Expansion of LV360 into Canada, Mexico, and European MarketsLifeVantage Announces Expansion of LV360 into Canada, Mexico, and European Markets
markets.businessinsider.com - February 7 at 9:25 AM
Are LifeVantage Corporations (NASDAQ:LFVN) Fundamentals Good Enough to Warrant Buying Given The Stocks Recent Weakness?Are LifeVantage Corporation's (NASDAQ:LFVN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
finance.yahoo.com - February 6 at 9:03 AM
LifeVantage Corporation (NASDAQ:LFVN) Q2 2024 Earnings Call TranscriptLifeVantage Corporation (NASDAQ:LFVN) Q2 2024 Earnings Call Transcript
finance.yahoo.com - February 1 at 1:15 PM
LifeVantage Corporation: LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024LifeVantage Corporation: LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024
finanznachrichten.de - January 31 at 10:27 AM
LifeVantage Non-GAAP EPS of $0.10 beats by $0.06, revenue of $51.6M misses by $3.05MLifeVantage Non-GAAP EPS of $0.10 beats by $0.06, revenue of $51.6M misses by $3.05M
msn.com - January 30 at 11:48 PM
Lifevantage: Fiscal Q2 Earnings SnapshotLifevantage: Fiscal Q2 Earnings Snapshot
wtop.com - January 30 at 6:47 PM
LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024
markets.businessinsider.com - January 30 at 6:47 PM
LifeVantage Q2 2024 Earnings PreviewLifeVantage Q2 2024 Earnings Preview
msn.com - January 29 at 7:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aeglea BioTherapeutics logo

Aeglea BioTherapeutics

NASDAQ:AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Biofrontera logo

Biofrontera

NASDAQ:BFRA
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
Chiasma logo

Chiasma

NASDAQ:CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Galera Therapeutics logo

Galera Therapeutics

NASDAQ:GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.